<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16726">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02026609</url>
  </required_header>
  <id_info>
    <org_study_id>#135318</org_study_id>
    <nct_id>NCT02026609</nct_id>
  </id_info>
  <brief_title>Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)</brief_title>
  <official_title>Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transjugular intrahepatic portosystemic shunt (TIPS) is the first-line therapy for patients
      with cirrhosis and refractory ascites. However, mental changes known as hepatic
      encephalopathy (HE) frequently occur after TIPS. There is no effective method to predict HE
      after TIPS. Oral glutamine challenge (OGC) and psychometric tests have been used to assess
      the risk for HE, but never in patients undergoing TIPS. Severe muscle loss may also
      predispose patients to HE. The aim of the present study is to assess if both the OGC and
      psychometric tests can accurately predict the development of overt HE after TIPS. Patients
      will be studied before TIPS and followed after TIPS for the development of HE. The role of
      muscle loss in favoring HE, as well as is possible reversibility after TIPS will also be
      investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In cirrhosis, up to 10% of patients develop refractory ascites. TIPS (transjugular
      intrahepatic portosystemic shunt) is the first-line therapy for these patients. However, 30%
      will go on to develop hepatic encephalopathy (HE) as a consequence of TIPS, and there is no
      effective method to predict this outcome. Oral glutamine challenge (OGC) is used to
      functionally assess ammonia metabolism, and the severity of porto-systemic
      collateralization, and it has been used to predict overt HE. Psychometric tests (i.e.
      Psychometric Hepatic Encephalopathy Score [PHES] and inhibitory control test) allow the
      identification of covert forms of HE and can also predict overt HE. Severe sarcopenia may
      also predispose patients to HE. The aim of the present study is to assess if both the degree
      of impairment in ammonia metabolism as estimated with the OGC, and cognitive status as
      determined by psychometric tests, can accurately predict the development of overt HE after
      TIPS. Patients will be studied before TIPS and followed after TIPS for the development of
      overt HE. The role of sarcopenia in favoring HE, as well as is possible reversibility after
      TIPS will also be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Overt hepatic encephalopathy</measure>
    <time_frame>up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Classified according to West Haven criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sarcopenia</measure>
    <time_frame>Baseline and 6 months post-TIPS</time_frame>
    <safety_issue>No</safety_issue>
    <description>According to CT scan L3 area of muscle mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Baseline and 6 months post-TIPS</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pedometer readings and physical activity questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Intake</measure>
    <time_frame>Baseline and 6 months post-TIPS</time_frame>
    <safety_issue>No</safety_issue>
    <description>Food frequency questionnaire (FFQ, NutritionQuest, Berkeley, CA)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Skeletal muscle trophic factors</measure>
    <time_frame>Baseline and 6 months post-TIPS</time_frame>
    <safety_issue>No</safety_issue>
    <description>IGF-1 and myostatin levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Glutaminase gene variations</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Genetic variations in the glutaminase gene (located at 2q-32-134) consisting of single nucleotide polymorphisms (SNPs) identifying a microsatellite of GCA repeats in the 5' untranslated region</description>
  </other_outcome>
  <other_outcome>
    <measure>Psychometric tests</measure>
    <time_frame>3 and 6 months post-TIPS</time_frame>
    <safety_issue>No</safety_issue>
    <description>Repeat PHES and ICT</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Refractory Ascites</condition>
  <condition>Hepatic Hydrothorax</condition>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>TIPS</arm_group_label>
    <description>Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral glutamine challenge</intervention_name>
    <description>Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine</description>
    <arm_group_label>TIPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychometric Tests</intervention_name>
    <description>PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)</description>
    <arm_group_label>TIPS</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, and PBMCs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients will be recruited from the Gastroenterology / Hepatology Clinics at
        UAMS and other participating centers. Those fulfilling inclusion/exclusion criteria will
        be invited to participate.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis (any etiology)

          -  Refractory ascites or hepatic hydrothorax and plan for TIPS placement

        Exclusion Criteria:

          -  Well-documented overt hepatic encephalopathy, either persistent or at the time of
             screening

          -  Any contraindication for TIPS placement

               -  Except for coagulopathy and thrombocytopenia (decided on an individual basis)

          -  Uncontrolled depression/anxiety disorder or use of antipsychotic drugs

          -  Active use of alcohol or illicit drugs

          -  History of dementia

          -  TIPS planned for another indication.

          -  Active alcoholic liver disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Duarte-Rojo, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andres Duarte-Rojo, MD, MSc</last_name>
    <phone>501.686.5175</phone>
    <email>aduarterojo@uams.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan A Dranoff, MD</last_name>
    <phone>501.686.5175</phone>
    <email>jadranoff@uams.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Duarte-Rojo, MD, MSc</last_name>
      <phone>501-686-5175</phone>
      <email>aduarterojo@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan A Dranoff, MD</last_name>
      <phone>501.686.5175</phone>
      <email>jadranoff@uams.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew G Deneke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James C Meek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan A Dranoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andres Duarte-Rojo, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher F Rose, PhD</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>35740</phone_ext>
      <email>christopher.rose@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Christopher F Rose, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Spahr, MD</last_name>
      <phone>+41223729340</phone>
      <email>Laurent.Spahr@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Laurent Spahr, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010 Jul;59(7):988-1000. doi: 10.1136/gut.2009.193227.</citation>
    <PMID>20581246</PMID>
  </reference>
  <reference>
    <citation>Romero-Gómez M, Jover M, Del Campo JA, Royo JL, Hoyas E, Galán JJ, Montoliu C, Baccaro E, Guevara M, Córdoba J, Soriano G, Navarro JM, Martínez-Sierra C, Grande L, Galindo A, Mira E, Mañes S, Ruiz A. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med. 2010 Sep 7;153(5):281-8. doi: 10.7326/0003-4819-153-5-201009070-00002.</citation>
    <PMID>20820037</PMID>
  </reference>
  <reference>
    <citation>Romero-Gómez M, Grande L, Camacho I, Benitez S, Irles JA, Castro M. Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. J Hepatol. 2002 Dec;37(6):781-7.</citation>
    <PMID>12445419</PMID>
  </reference>
  <reference>
    <citation>Ditisheim S, Giostra E, Burkhard PR, Goossens N, Mentha G, Hadengue A, Spahr L. A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis. BMC Gastroenterol. 2011 Dec 8;11:134. doi: 10.1186/1471-230X-11-134.</citation>
    <PMID>22151412</PMID>
  </reference>
  <reference>
    <citation>Duarte-Rojo A, Estradas J, Hernández-Ramos R, Ponce-de-León S, Córdoba J, Torre A. Validation of the psychometric hepatic encephalopathy score (PHES) for identifying patients with minimal hepatic encephalopathy. Dig Dis Sci. 2011 Oct;56(10):3014-23. doi: 10.1007/s10620-011-1684-0. Epub 2011 Apr 3.</citation>
    <PMID>21461913</PMID>
  </reference>
  <reference>
    <citation>Bajaj JS, Saeian K, Verber MD, Hischke D, Hoffmann RG, Franco J, Varma RR, Rao SM. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol. 2007 Apr;102(4):754-60. Epub 2007 Jan 11.</citation>
    <PMID>17222319</PMID>
  </reference>
  <reference>
    <citation>Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, Esfandiari N, Baracos V, Montano-Loza AJ, Myers RP. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012 Oct;18(10):1209-16. doi: 10.1002/lt.23495.</citation>
    <PMID>22740290</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>December 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TIPS</keyword>
  <keyword>Hepatic encephalopathy</keyword>
  <keyword>Oral glutamine challenge</keyword>
  <keyword>Psychometric tests</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Cirrhosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Hydrothorax</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Brain Damage, Chronic</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
